Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors

Aydın, Büşra; Beklen, Hande; Arğa, Kazım Yalçın; Bayraklı, Fatih; Turanlı, Beste

doi:10.1007/s40618-022-01923-2

Cited by 4 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DNA methylation and expression levels of two genes, family with sequence similarity 90 member A1 ( FAM90A1 ) gene and inhibitor of growth family member 2 (ING2) gene, are related to nfPitNET regrowth, suggesting the methylation status and expression levels as biomarkers that may predict nfPitNET behaviors [ 63 ]. Another study integrating epigenome and transcriptome data found DNA methylation alterations and differential gene expression profiles in nfPitNETs compared to normal pituitary tissues as well as key protein molecules in the protein-protein interaction network, which can be novel therapeutic targets [ 64 ].…”

Section: Pathogenesismentioning

confidence: 99%

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors

Whyte,

Nezu,

Chik

et al. 2023

Endocrinol Metab

View full text Add to dashboard Cite

Pituitary neuroendocrine tumors (PitNETs) are the third most frequently diagnosed intracranial tumors, with nonfunctioning PitNETs (nfPitNETs) accounting for 30% of all pituitary tumors and representing the most common type of macroPitNETs. NfPitNETs are usually benign tumors with no evidence of hormone oversecretion except for hyperprolactinemia secondary to pituitary stalk compression. Due to this, they do not typically present with clinical syndromes like acromegaly, Cushing’s disease or hyperthyroidism and instead are identified incidentally on imaging or from symptoms of mass effects (headache, vision changes, apoplexy). With the lack of effective medical interventions, first-line treatment is transsphenoidal surgical resection, however, nfPitNETs often have supra- or parasellar extension, and total resection of the tumor is often not possible, resulting in residual tumor regrowth or reoccurrence. While functional PitNETs can be easily followed for recurrence using hormonal biomarkers, there is no similar parameter to predict recurrence in nfPitNETs, hence delaying early recognition and timely management. Therefore, there is a need to identify prognostic biomarkers that can be used for patient surveillance and as therapeutic targets. This review focuses on summarizing the current evidence on nfPitNETs, with a special focus on potential new biomarkers and therapeutics.

show abstract

Section: Pathogenesismentioning

confidence: 99%

Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors

Whyte,

Nezu,

Chik

et al. 2023

Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Second, meaningful features were extracted using various network-based analytical methods, including proximity to disease-associated genes, as well as unbiased approaches based on propagation, topological metrics, and module detection. While these methods have been extensively applied in drug repositioning scenarios [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , their effectiveness in target repositioning remains to be better characterised. Using the extracted features, various machine learning algorithms were then trained, and the predictive power of each approach was evaluated.…”

Section: Introductionmentioning

confidence: 99%